Suppr超能文献

解读胸主动脉瘤和夹层中 MYH11 基因拷贝数变异:临床基因检测中变异错误注释带来的启示

Interpreting MYH11 Copy Number Variation in Thoracic Aortic Aneurysm and Dissection: Insights From the Misannotation of Variants in Clinical Genetic Tests.

作者信息

Schwartzman William E, Hujoel Margaux L A, Channaoui Nadine, Lee-Kim Vivian, Loh Po-Ru, Gupta Rajat M

机构信息

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Data Sciences, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

JACC Case Rep. 2025 Mar 19;30(6 Pt 1):102973. doi: 10.1016/j.jaccas.2024.102973. Epub 2025 Jan 22.

Abstract

Thoracic aortic aneurysm and dissection (TAAD) is a rare but often fatal vascular disease. A family history of TAAD increases risk, and several genes are linked to risk of both aneurysm and dissection. The current AHA/ACC guidelines for management of TAAD include genetic testing for affected individuals with no other risk factors such as hypertension or bicuspid aortic valve. However, interpretation of genetic testing results, even for validated TAAD genes, can be challenging. Herein we show 2 TAAD cases in patients with MYH11 copy number variations. These cases demonstrate that MYH11 deletion is often miscategorized as pathogenic, while MYH11 duplication is miscategorized as benign. We then confirm the association of chromosome 16p13.1 duplications which include MYH11 and aortic dissection in the UK Biobank clinical registry. These cases underscore the risk of misannotation of MYH11 structural variants in the evaluation of genetic risk for TAAD patients.

摘要

胸主动脉瘤和夹层(TAAD)是一种罕见但往往致命的血管疾病。TAAD家族史会增加患病风险,并且有几种基因与动脉瘤和夹层的风险相关。当前美国心脏协会/美国心脏病学会(AHA/ACC)关于TAAD管理的指南包括对没有高血压或二叶式主动脉瓣等其他风险因素的受影响个体进行基因检测。然而,即使对于经过验证的TAAD相关基因,基因检测结果的解读也可能具有挑战性。在此我们展示了2例存在MYH11拷贝数变异的TAAD病例。这些病例表明,MYH11缺失常被错误分类为致病性变异,而MYH11重复则被错误分类为良性变异。然后我们在英国生物银行临床登记处证实了包含MYH11的16号染色体p13.1区域重复与主动脉夹层之间的关联。这些病例强调了在评估TAAD患者遗传风险时MYH11结构变异错误注释的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecfd/12011163/a07e2bdf4e00/ga1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验